LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
40 of Lineage Cell Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 6, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 6, 2026 | Aug 6, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 9, 2026 | Jun 12, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 12, 2026 | SEC EDGAR |
| Current report | 8-K | May 12, 2026 | May 12, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | Apr 29, 2026 | Apr 29, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 11, 2026 | Mar 11, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 5, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 5, 2026 | Mar 5, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 28, 2025 | Nov 28, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 20, 2025 | Nov 24, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 12, 2025 | Nov 12, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2025 | Nov 6, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 6, 2025 | Nov 6, 2025 | SEC EDGAR |
| Current report | 8-K | Aug 26, 2025 | Aug 26, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2025 | Aug 12, 2025 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2025 | Aug 12, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 26, 2025 | Jul 2, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 23, 2025 | Jun 23, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 3, 2025 | Jun 9, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2025 | May 13, 2025 | SEC EDGAR |
| Current report | 8-K | May 13, 2025 | May 13, 2025 | SEC EDGAR |
| Current report | 8-K | May 1, 2025 | May 1, 2025 | SEC EDGAR |
| Proxy statement | DEF 14A | Jun 26, 2025 | Apr 29, 2025 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2024 | Mar 10, 2025 | SEC EDGAR |
| Current report | 8-K | Mar 10, 2025 | Mar 10, 2025 | SEC EDGAR |
| Current report | 8-K | Jan 27, 2025 | Jan 27, 2025 | SEC EDGAR |
| Proxy statement | DEF 14A | Dec 9, 2024 | Dec 9, 2024 | SEC EDGAR |
| Current report | 8-K | Nov 19, 2024 | Nov 20, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2024 | Nov 14, 2024 | SEC EDGAR |
| Current report | 8-K | Nov 14, 2024 | Nov 14, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2024 | Aug 8, 2024 | SEC EDGAR |
| Current report | 8-K | Aug 8, 2024 | Aug 8, 2024 | SEC EDGAR |
| Current report | 8-K | Jun 11, 2024 | Jun 14, 2024 | SEC EDGAR |
| Current report | 8-K | Jun 11, 2024 | Jun 13, 2024 | SEC EDGAR |
| Current report | 8-K | May 14, 2024 | May 14, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2024 | May 9, 2024 | SEC EDGAR |
| Current report | 8-K | May 9, 2024 | May 9, 2024 | SEC EDGAR |
| Proxy statement | DEF 14A | Jun 11, 2024 | Apr 29, 2024 | SEC EDGAR |
| Current report | 8-K | Mar 12, 2024 | Mar 22, 2024 | SEC EDGAR |